Cipla’s New York plant gets FDA no-action classification
FDA gave Cipla’s InvaGen plant in Hauppauge a No Action Indicated classification after its October 2026 inspection, easing regulatory uncertainty without approving any drug or product.

U/REGULATI
12 filings logged
FDA, EMA and global regulators — approvals, complete response letters, advisory committees, guidance and policy.
FDA gave Cipla’s InvaGen plant in Hauppauge a No Action Indicated classification after its October 2026 inspection, easing regulatory uncertainty without approving any drug or product.
